Analysis of survival of HIV/AIDS aged 50 years and above in Chengdu after antiretroviral therapy

SHI Ya-ying; ZHOU Min; WU Xue-qing; HE Shi-jiao; LIU Fang; ZHU Yan-feng

doi:10.16462/j.cnki.zhjbkz.2020.12.007

Volume 24 Issue 12

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2020 > 24(12): 1398-1402,1469

SHI Ya-ying, ZHOU Min, WU Xue-qing, HE Shi-jiao, LIU Fang, ZHU Yan-feng. Analysis of survival of HIV/AIDS aged 50 years and above in Chengdu after antiretroviral therapy[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(12): 1398-1402,1469. doi: 10.16462/j.cnki.zhjbkz.2020.12.007

Citation:

SHI Ya-ying, ZHOU Min, WU Xue-qing, HE Shi-jiao, LIU Fang, ZHU Yan-feng. Analysis of survival of HIV/AIDS aged 50 years and above in Chengdu after antiretroviral therapy[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(12): 1398-1402,1469. doi: 10.16462/j.cnki.zhjbkz.2020.12.007

Citation:

PDF( 960 KB)

Analysis of survival of HIV/AIDS aged 50 years and above in Chengdu after antiretroviral therapy

doi: 10.16462/j.cnki.zhjbkz.2020.12.007

1.
Department of STD/AIDS Control and Prevention, Chengdu Center for Disease Control and Prevention, Chengdu 610041, China
2.
School of Public Health, China Medical university, Shenyang 110001, China
3.
School of Public Health, Chengdu Medical College, Chengdu 610041, China

More Information

Corresponding author: ZHU Yan-feng, E-mail: cmc_zhuyanfeng@163.com
Received Date: 2019-11-12
Rev Recd Date: 2020-03-02
Publish Date: 2020-12-10

Abstract

Abstract

Objective To understand the survival of HIV/AIDS aged 50 years and above in Chengdu after receiving antiretroviral therapy(ART), and to explore the factors affecting the survival of HIV/AIDS aged 50 years and above after ART, so as to provide the basis for the health authorities at all levels to formulate the treatment policy for HIV/AIDS aged 50 years and above. Methods The HIV/AIDS aged 50 years and above who were receiving ART in Chengdu from 2010 to 2018 were selected. Life-table method was used to describe the survival situation. Survival analysis method was used to stratify the study subjects according to the factors by the Cox risk regression model. Results The cumulative survival rate decreased from 0.97 to 0.91 within 20 months after treatment, and the cumulative survival rate was 0.82 at 9 years up to the end point of observation. Cox multivariate analysis showed that the risk of death in women was 0.689 times than in men. The aged 70 years and above was 4.037 times than the aged from 50 to 54 years old. Spinsterhood and divorced were 1.909 and 1.269 times than married. The college and above was 0.403 times than illiteracy. The first CD4⁺T cell test value of >500 /mm³ was 0.318 times higher than < 100 /mm³. Conclusions The survival rate of AIDS patients aged 50 years and above after ART is high. The factors such as age, education level and marital status affect the survival of AIDS patients aged 50 years and above. Corresponding treatment measures and publicity means should be developed according to the actual situation in Chengdu.
- HIV/AIDS,
- Antiviral therapy,
- Survival analysis

FullText(HTML)

References(18)

References

[1]	陈婧, 徐敏, 赵啸, 等.北京市2005-2015年艾滋病抗病毒治疗患者生存及其影响因素[J].中华疾病控制杂志, 2018, 22(12):1225-1228. DOI: 10.16462/j.cnki.zhjbkz.2018.12.006. Chen J, Xu M, Zhao X, et al. Analysis of the survival conditions of HIV/AIDS patients receiving antiretroviral therapy in Beijing in 2005-2015 and the related factors[J]. Chin J Dis Control Prev, 2018, 22(12):1225-1228. DOI: 10.16462/j.cnki.zhjbkz.2018.12.006.
[2]	裴晓迪, 袁风顺, 刘莉, 等. 2012-2017年四川省50岁及以上艾滋病病毒感染者/艾滋病患者流行特征分析[J].预防医学情报杂志, 2019, 35(6):559-564. http://d.wanfangdata.com.cn/periodical/yfyxqbzz201906009 Pei XD, Yuan FS, Liu L, et al. Analysis of epidemiological characteristics of HIV/AIDS patients 50 years old and above in Sichuan Province from 2012 to 2017[J]. J Prevent Med Inf, 2019, 35(6):559-564. http://d.wanfangdata.com.cn/periodical/yfyxqbzz201906009
[3]	罗若愚, 钟易霖, 踪家峰.转型期成都市社会空间结构研究-基于第六次人口普查数据的分析[J].地域研究与开发, 2018, 37(4):73-79. DOI: 10.3969/j.issn.1003-2363.2018.04.013. Luo RY, Zhong YL, Zong JF. Study on social spatial structure of Chengdu in the transitional period: based on the data of sixth national population census in China[J]. Areal Research and Development, 2018, 37(4):73-79. DOI: 10.3969/j.issn.1003-2363.2018.04.013.
[4]	鹿茸, 施雅莹, 段振华. 2010-2014年成都市50岁及以上男性艾滋病疫情分析[J].预防医学情报杂志, 2016, 32(11):1137-1139. http://d.wanfangdata.com.cn/periodical/yfyxqbzz201611002 Lu R, Shi YY, Duan ZH. The HIV/AIDS epidemic of men aged 50 and older in Chengdu, 2010-2014[J]. J Prevent Med Inf, 2016, 32(11):1137-1139. http://d.wanfangdata.com.cn/periodical/yfyxqbzz201611002
[5]	梁飞立, 何艳英, 黄绍标, 等.老年艾滋病抗病毒治疗六年生存情况及其影响因素分析[J].中华临床医师杂志(电子版), 2012, 6(20):6494-6496. DOI: 10.3877/cma.j.issn.1674-0785.2012.20.064. Liang FL, He YY, Huang SB, et al. Analysis on the survival and influencing factors of six years of antiviral treatment for AIDS in the elderly[J]. Chin J Clinicians(Electronic Edition), 2012, 6(20):6494-6496. DOI: 10.3877/cma.j.issn.1674-0785.2012.20.064.
[6]	郑武, 笪琴, 汤恒, 等.湖北省接受艾滋病抗病毒治疗的老年患者生存情况分析[J].实用预防医学, 2018, 25(2):176-180. DOI: 10.3969/j.issn.1006-3110.2018.02.014. Zhen W, Da Q, Tang H, et al. Survival status of elderly HIV/AIDS patients receiving highly active antiretroviral therapy in Hubei Province[J]. Pract Prevent Med, 2018, 25(2):176-180. DOI: 10.3969/j.issn.1006-3110.2018.02.014.
[7]	周超, 陈宗良, 吴国辉, 等. 2014-2018年重庆市中老年艾滋病抗病毒治疗患者生存状况分析[J].预防医学情报杂志, 2019, 35(12):1379-1383. http://d.wanfangdata.com.cn/periodical/yfyxqbzz201912010 Zhou C, Chen ZL, Wu GH, et al. Analysis of the survival conditions and associated factors of middle-aged and older HIV/AIDS patients receiving antiretroviral therapy in Chongqing City from 2014 to 2018[J]. J Prevent Med Inf, 2019, 35(12):1379-1383. http://d.wanfangdata.com.cn/periodical/yfyxqbzz201912010
[8]	王丽艳, 秦倩倩, 葛琳, 等.我国50岁及以上艾滋病病毒感染者/艾滋病患者特征分析[J].中华流行病学杂志, 2016, 37(2):222-226. DOI: 10.3760/cma.j.issn.0254-6450.2016.02.015. Wang LY, Qin QQ, Ge L, et al. Characteristics of HIV infections among over 50-year-olds population in China[J]. Chin J Epidemiol, 2016, 37(2):222-226. DOI: 10.3760/cma.j.issn.0254-6450.2016.02.015.
[9]	袁风顺, 罗映娟, 胡莹, 等.四川省2011-2015年报告的50岁及以上HIV/AIDS病例相关分析[J].中国艾滋病性病, 2016, 22(12):968-970. DOI: 10.13419/j.cnki.aids.2016.12.08. Yuan FS, Luo YJ, Hu Y, et al. Analysis of the newly reported HIV/AIDS cases at and above≥50 years old from 2011 to 2015 in Sichuan[J]. Chin J AIDS STD, 2016, 22(12):968-970. DOI: 10.13419/j.cnki.aids.2016.12.08.
[10]	施雅莹, 何勤英, 刘芳, 等.成都市艾滋病双阳家庭夫妻双方的生存时间及影响因素分析[J].成都学院学医报, 2018, 13(6):743-748, 754. DOI: 10.3969/j.issn.1674-2257.2018.06.022. Shi YY, He QY, Liu F, et al. Analysis of survival time and its influencing factors on couples of HIV/AIDS spouse positive family in Chengdu[J]. Journal of Chengdu Medical College, 2018, 13(6):743-748, 754. DOI: 10.3969/j.issn.1674-2257.2018.06.022.
[11]	姚书杰, 吕娅妮, 王莉, 等.辽宁省2003-2015年7255例艾滋病抗病毒治疗患者的生存分析[J].中华疾病控制杂志, 2016, 20(12):1203-1207. DOI: 10.16462/j.cnki.zhjbkz.2016.12.005. Yao SJ, Lv YN, Wang L, et al. The survival analysis in 7 255 AIDS patients on antiretroviral therapy in Liaoning Province in 2003-2015[J]. Chin J Dis Control Prev, 2016, 20(12):1203-1207. DOI: 10.16462/j.cnki.zhjbkz.2016.12.005.
[12]	Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies[J]. Lancet, 2009, 373(9672):1352-1363. DOI: 10.1016/S0140-6736(09)60612-7.
[13]	Morna C, Michael S, Daniela Belen G, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study[J]. PloS Med, 2012, 9(9):e1001304. DOI: 10.1371/journal.pmed.1001304.
[14]	杨文杰, 樊盼英, 梁妍, 等. 2005-2014年河南省15岁以上艾滋病患者抗病毒治疗后生存分析[J].中华预防医学杂志, 2015, 49(12):1061-1066. DOI: 10.3760/cma.j.issn.0253-9624.2015.12.009. Yang WJ, Fan PY, Liang Y, et al. Survival analysis of AIDS patients of 15 years or above years old after initiation antiretroviral treatment in Henan province during 2005 to 2014[J]. Chin J Prevent Med, 2015, 49(12):1061-1066. DOI: 10.3760/cma.j.issn.0253-9624.2015.12.009.
[15]	Reniers G, Slaymaker E, Nakiyingi-Miiro J, et al. Mortality trends in the era of antiretroviral therapy: evidence from the Network for Analysing Longitudinal Population based HIV/AIDS data on Africa (ALPHA)[J]. AIDS, 2014, Suppl4:S533-542. DOI: 10.1097/QAD.0000000000000496.
[16]	Edwards JK, Cole SR, Westreich D, et al. Age at entry into care, timing of antiretroviral therapy initiation, and 10-year mortality among HIV-seropositive adults in the United States[J]. Clin Infect Dis, 2015, 61(7):1189-1195. DOI: 10.1093/cid/civ463.
[17]	麦毓麟.中国HIV/AIDS病人接受ART的脱失率和生存分析[D].北京: 北京协和医学院, 2016. Mai YL. Loss rate and survival of HIV/AIDS patients receiving ART in China[D]. Beijing: Peking Union Medical College, 2016.
[18]	高良敏, 付金翠, 李世福, 等. 50岁以上人群HIV流行特征与相关危险因素的系统性分析[J].皮肤病与性病, 2016, 38(1):36-42. DOI: 10.3969/j.issn.1002-1310.2016.01.013. Gang LM, Fu JC, Li SF, et al. Systematic analysis of HIV prevalence characteristics and associated risk factors in people over 50 years of age[J]. J Dermatology and Venereology, 2016, 38(1):26-42. DOI: 10.3969/j.issn.1002-1310.2016.01.013.